Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 8/20 | 0.43 |
| ▸ | RARB | P10826 | 8/20 | 0.43 |
| ▸ | RARG | P13631 | 5/20 | 0.43 |
| ▸ | RXRA | P19793 | 11/20 | 0.39 |
| ▸ | RXRG | P48443 | 7/20 | 0.39 |
| ▸ | RXRB | P28702 | 6/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7757713 | 1.00 | RARA (0.43) | RARARARBRARGRXRARXRG | |
| SCHEMBL7751700 | 0.90 | CYP3A4 (0.43) | RARARARBRARGRXRARXRG | |
| SCHEMBL7751702 | 0.90 | CYP3A4 (0.43) | RARARARBRARGRXRARXRG | |
| SCHEMBL7754972 | 0.87 | RARB (0.53) | RARARARBRARGRXRARXRG | |
| SCHEMBL7754968 | 0.87 | RARB (0.53) | RARARARBRARGRXRARXRG | |
| SCHEMBL7781181 | 0.81 | RXRA (0.40) | RARBRARGRXRARXRGRXRB | |
| SCHEMBL7755801 | 0.81 | RXRA (0.40) | RARBRARGRXRARXRGRXRB | |
| SCHEMBL7754746 | 0.76 | RXRA (0.57) | RARARARBRARGRXRARXRG | |
| SCHEMBL7754748 | 0.76 | RXRA (0.57) | RARARARBRARGRXRARXRG | |
| SCHEMBL7755874 | 0.74 | RXRA (0.47) | RARARARBRARGRXRARXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010034448-A1 | New compounds, their preparation and use | MURRAY ANTHONY (GB) | 2001-10-25 | — | — | US | disclosed |
| EP-1077920-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058487-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034448-A1 | New compounds, their preparation and use | GPR119, SLC5A1, SLC5A2 | RARA 1387/4885RARB 1627/4885RARG 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.